Theravance, Inc, which spun off from Theravance Biopharma in 2013, will now be known as “Innoviva” and will trade on NASDAQ under the symbol “INVA,” the company said. Innoviva is partnered with GSK on the Relvar/Breo Ellipta fluticasone furoate/vilanterol DPI, the Anoro Ellipta umeclidinium/vilanterol DPI, and a vilanterol monotherapy DPI in development.
Innoviva President and CEO Michael W. Aguiar said, “We are proud to launch our new corporate identity as Innoviva, which we believe clearly reflects our business strategy. The name represents the fusion of our innovative approach to asset management with our commitment to improving the lives of patients by helping to bring impactful medicines to market. We believe 2016 will be an exciting year for Innoviva as we expect to continue to see positive script trends and improving payer coverage in the US market for both Relvar/Breo Ellipta and Anoro Ellipta, and remain committed to maximize the commercial potential of our portfolio in partnership with GSK.”
Read the Innoviva press release.
